Olanzapine vs Aripiprazole: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Olanzapine blocks dopamine D2, serotonin 5-HT2A/2C, histamine H1, and muscarinic receptors — one of the broadest receptor binding profiles of any antipsychotic. The H1 and 5-HT2C blockade drives severe appetite stimulation and insulin resistance, creating metabolic syndrome that depletes B vitamins through increased glucose metabolism demand, reduces vitamin D through obesity-related sequestration in adipose tissue, and impairs CoQ10 through mitochondrial stress from dyslipidemia. CTD gene interaction data confirms effects across metabolic, inflammatory, and mitochondrial pathways.
Olanzapine has 60% bioavailability with a 30-hour half-life and 93% protein binding, providing continuous receptor blockade that sustains metabolic disruption around the clock.
- ✓Highly effective for treatment-resistant schizophrenia and acute mania — often works when other antipsychotics fail
- ✓30-hour half-life allows once-daily dosing with stable blood levels
- ✓Available as IM and orally disintegrating forms for acute agitation management
- ✓Rapid onset of action for acute psychotic episodes
- ✗Worst metabolic profile of any antipsychotic — average 12–15 lb weight gain in the first year
- ✗FAERS death-associated rate of 9.6% — reflecting severe metabolic complications
- ✗Drives insulin resistance that can progress to type 2 diabetes within months
- ✗Vitamin D sequestration in expanding adipose tissue creates functional deficiency even with adequate intake
Patients with treatment-resistant psychosis who have failed other antipsychotics and accept the metabolic risk with aggressive monitoring and nutrient supplementation.
Aripiprazole is a unique partial dopamine D2 agonist — rather than fully blocking dopamine, it modulates the signal. This fundamentally different mechanism produces far less metabolic disruption: minimal H1 blockade means less appetite stimulation, and partial D2 agonism avoids the prolactin elevation and metabolic syndrome that full D2 antagonists cause. The nutrient depletions still occur through serotonin 5-HT2A antagonism and general antipsychotic-class effects on mitochondrial function, but at dramatically lower severity.
Aripiprazole achieves 87% bioavailability with an exceptionally long 75-hour half-life, providing the most stable blood levels of any antipsychotic — beneficial for adherence but meaning the drug takes weeks to fully clear.
- ✓Lowest metabolic risk of any antipsychotic — minimal weight gain, minimal insulin resistance
- ✓FAERS death-associated rate of only 1.8% — 5x lower than olanzapine's 9.6%
- ✓87% bioavailability and 75-hour half-life provide the most stable antipsychotic blood levels available
- ✓Partial dopamine agonism avoids the prolactin elevation that causes sexual dysfunction with other antipsychotics
- ✗Less effective for acute psychosis and treatment-resistant schizophrenia compared to olanzapine
- ✗75-hour half-life means 2–3 weeks to reach steady state and 2–3 weeks to clear if side effects develop
- ✗Akathisia (restless agitation) is more common with aripiprazole than olanzapine — can be treatment-limiting
- ✗Still depletes the same four nutrient categories, just at lower severity
First-line antipsychotic treatment for patients who prioritize metabolic safety, weight management, and the lowest possible cardiovascular and nutrient depletion risk.
Feature Comparison
| Feature | Olanzapine | Aripiprazole |
|---|---|---|
| Drug Class | Atypical antipsychotic (multi-receptor antagonist) | Atypical antipsychotic (partial D2 agonist) |
| Nutrients Affected | 4 — CoQ10, vitamin D, B vitamins, metabolic | 4 — CoQ10, vitamin D, B vitamins, metabolic |
| Metabolic Severity | Severe (worst in class) | Minimal (best in class) |
| Half-Life | 30 hours | 75 hours |
| Bioavailability | 60% | 87% |
| FAERS Death Rate | 9.6% | 1.8% |
| Weight Gain | 12–15 lbs first year (average) | Minimal (weight-neutral) |
| Primary Role | Treatment-resistant psychosis, acute mania | First-line psychosis, bipolar maintenance, MDD augmentation |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both antipsychotics affect the same four nutrient categories, but the magnitude is not comparable. Olanzapine's aggressive H1/5-HT2C blockade creates the worst metabolic syndrome in psychiatry — 12–15 lbs weight gain, insulin resistance, dyslipidemia — that drives cascading nutrient depletion through obesity, inflammation, and mitochondrial stress. Aripiprazole's partial dopamine agonism produces a fundamentally different metabolic impact: weight-neutral, minimal insulin disruption, and a FAERS death-associated rate of 1.8% versus olanzapine's 9.6%. For nutrient preservation, aripiprazole is categorically superior. Olanzapine is reserved for treatment-resistant psychosis where its uniquely potent efficacy justifies the metabolic cost — always with aggressive metabolic monitoring, B-complex supplementation, vitamin D repletion, and CoQ10 support.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): gene interactions for both drugs affecting dopaminergic, serotonergic, and metabolic pathways
- [2]FAERS (FDA Adverse Event Reporting System): olanzapine 9.6% death-associated rate; aripiprazole 1.8% death-associated rate
- [3]ChEMBL bioactivity database: receptor binding profiles and clinical trial data for both antipsychotics
- [4]PubMed PMID 15741488 — Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1-93
- [5]PharmGKB pharmacogenomics database: CYP2D6 and CYP3A4 metabolism annotations for both drugs
Check your medications
Check Free →